A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Active, not recruiting · Phase 1 · NCT06244485
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $2.8M
- U.S. investigators named
- 17
- Sites paid
- 21
- Planned or actual enrollment
- 210
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- Valemetostat tosylate (drug), T-DXd (drug), Dato-DXd (drug)
- Dates
- Started 2024-02-22; completion 2028-11-01
- Results posted
- Not yet
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd antibody-drug conjugates (ADC) in participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $2.8M in research payments for this study in 2025 (1,940 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Charles H. Redfern, M.D. Hematology & Oncology · San Diego, CA
- Timothy R. Brown, M.D. General Surgery · Canon City, CO
- Jyoti Malhotra, M.D, MPH Hematology & Oncology · New Haven, CT
- Andrew M. Schneider, M.D. Hematology & Oncology · Tamarac, FL
- Naoto Ueno, M.D. PHD Medical Oncology · Honolulu, HI
- Alissa J. Cooper, MD Medical Oncology · Boston, MA
- Jacob M. Sands, MD Hematology & Oncology · Burlington, MA
- Alex A. Adjei, MD PHD Medical Oncology · Rochester, MN
- Elizabeth C. Dees, MD Medical Oncology · Chapel Hill, NC
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Rachel E. Sanborn, MD Medical Oncology · Portland, OR
- Funda Meric, M.D. General Surgery · Houston, TX
- Reva Schneider Medical Oncology · Dallas, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Andrew L. Coveler, MD Medical Oncology · Seattle, WA
- Hui-zi Chen, M.D., PH.D. Medical Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Valkyrie Clinical Trials $838,195
- Dana-Farber Cancer Institute $431,287
- Next Oncology-San Antonio $368,346
- City of Hope National Medical Ctr $277,394
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $200,794
- University of Washington Medical Ctr, WA $144,370
- Sharp Memorial Hospital $128,641
- Medical College of Wisconsin $105,520
- Ut MD Anderson Cancer Center $77,813
- Cleveland Clinic, OH $72,723
- University of North Carolina at Chapel Hill $58,492
- Ut Southwestern Med Ctr-Zale Lipshy $37,838
- Providence Portland Medical Center, OR $26,713
- Froedtert Memorial Lutheran Hospital, WI $2,535
- Clinical Research Alliance $2,254
- Mary Crowley Cancer Research $1,943
- The University of Texas Southwestern Medical Center at Dallas $1,775
- The Queens Medical Center, HI $1,775
- Brcr Global $1,486
- Memorial Hospital for Cancer and All $582
- Unc Hospitals, NC $307
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.